An Evidence-Based Approach to Managing Chemotherapy-Induced Nausea and Vomiting - Post Test

Name:
Street Address:
City: State/Province:
ZIP/Postal Code: Country:
Telephone #: Email:
I am a Registered Nurse
Please email me when more CME becomes available.
Please add me to the Oncolink Newsletter
  1. Chemotherapy induced nausea and vomiting (CINV) is a distressing side effect of cancer treatment that significantly affects quality of life.
    1. True
    2. False

  2. Acute CINV occurs:
    1. More than 24 hours after chemotherapy administration
    2. Prior to arriving at the clinic for chemotherapy administration
    3. Within 24 hours of receiving chemotherapy
    4. None of the above

  3. Activation of the vomiting center in CINV is thought to arise from the:
    1. Gastrointestinal tract
    2. Chemoreceptor trigger zone
    3. Vestibular-cerebellar pathway
    4. A & B

  4. This 5-HT3 antagonist has the longest half-life (40 hours).
    1. ondansetron
    2. dolasetron
    3. palonosetron
    4. granisetron

  5. Neurokinin 1 receptor antagonists are used for preventing delayed nausea and vomiting and work by blocking:
    1. 5-HT3 receptors
    2. Substance P
    3. Pain receptors
    4. The perception of nausea

  6. Corticosteroids are an important component of CINV therapy. The following statements are true regarding these medications:
    1. Corticosteroids are effective for treating acute and delayed CINV
    2. They can be given alone or in combination with other medications
    3. Corticosteroids potentiate the action of other antiemetics
    4. All of the above

  7. Steps to improving control of CINV in practice includes all of the following except:
    1. Improve patient assessment for CINV
    2. Personalize therapy based on risk factors, cost and convenience
    3. Only need to assess after first cycle of therapy
    4. Improved adherence to antiemetic guidelines

  8. Chemotherapies that are considered highly emetogenic have a >90% incidence of CINV if prophylactic antiemetics are not given.
    1. True
    2. False

  9. Guidelines for the prevention and treatment of CINV have been developed by:
    1. Multinational Association of Supportive Care in Cancer (MASCC)
    2. American Society of Clinical Oncology (ASCO)
    3. The National Comprehensive Cancer Network (NCCN)
    4. All of the above

  10. To improve assessment of the patient with CINV, our assessment should include:
    1. Evaluate the patient in the clinic and follow up by phone
    2. Engage the patient in the assessment through visual analogue scales and diaries
    3. Assess for CINV after every cycle of therapy, regardless of the presence or absence of CINV in previous cycles
    4. All of the above

Please hit submit only once. The results may take a few minutes to load on slower connections.

English

I Wish You Knew

The Controversy of Screening

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información